Entyvio

Chemical Namevedolizumab
Dosage FormInjection (intravenous; 300 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyTakeda
Approval Year2014

Indication

  • For adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
  • For adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Last updated on 7/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Entyvio (vedolizumab) Prescribing Information.2021Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
Document TitleYearSource
Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis.2022Intestinal Research
Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: systematic review and network meta-analysis of randomized controlled trials.2022Inflammatory Bowel Diseases
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. 2022BMC Gastroenterology
The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel disease—a systematic literature review.2022Pharmaceutics
Systematic review and network meta-analysis: comparative efficacy and safety of biosimilars, biologics and JAK1 inhibitors for active Crohn disease.2021Frontiers in Pharmacology
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.2021Expert Review of Gastroenterology & Hepatology
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis.2021Digestive and Liver Disease
Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis.2020Clinical Gastroenterology and Hepatology
Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis.2020Clinical Gastroenterology and Hepatology
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.2019Scandinavian Journal of Gastroenterology
Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.2019Alimentary Pharmacology & Therapeutics
Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review.2019Journal of Crohn’s and Colitis
Safety of vedolizumab in liver transplant recipients: a systematic review.2019United European Gastroenterology Journal
Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease.2018Inflammatory Bowel Diseases
Primary non-response to tumor necrosis factor antagonists is associated with Inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis.2018Journal of Crohn's and Colitis
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. 2018Cochrane Database of Systematic Reviews
Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease.2018Journal of Crohn's and Colitis
Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis.2017Alimentary Pharmacology & Therapeutics
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials.2017Alimentary Pharmacology & Therapeutics